RXDX 107

Drug Profile

RXDX 107

Alternative Names: CEP-40125; RXDX-107

Latest Information Update: 26 Jun 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Cephalon
  • Developer Ignyta
  • Class Antineoplastics; Benzimidazoles; Butyric acids; Nitrogen mustard compounds; Nitrosourea compounds; Small molecules
  • Mechanism of Action Apoptosis stimulants; DNA cross linking agents; DNA synthesis inhibitors; Mitosis modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Discontinued Solid tumours

Most Recent Events

  • 08 Feb 2018 Ignyta has been acquired by Roche
  • 23 Sep 2016 Ignyta terminates phase I trial in Solid tumours (Late-stage disease) in USA (NCT02548390)
  • 23 Feb 2016 Discontinued - Phase-I for Solid tumours (Late-stage disease) in USA (IV)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top